What is Daratumumab: Uses, Dosage, Side Effects and More

Daratumumab is a powerful cancer medication that helps your immune system fight multiple myeloma, a type of blood cancer. This targeted therapy works by attaching to specific proteins on cancer cells, marking them for destruction by your body's natural defense system.

If you or someone you care about has been prescribed daratumumab, you likely have many questions about what to expect. This medication represents a significant advancement in cancer treatment, and understanding how it works can help you feel more confident about your care journey.

What is Daratumumab?

Daratumumab is a type of immunotherapy called a monoclonal antibody that treats certain blood cancers. Think of it as a highly trained scout that finds cancer cells hiding in your body and signals your immune system to attack them.

The medication is given through an IV infusion, which means it's delivered directly into your bloodstream through a vein. This method ensures the medicine reaches cancer cells throughout your body effectively. Daratumumab belongs to a class of drugs called CD38-directed cytolytic antibodies, but what matters most is that it's designed to work with your immune system rather than against it.

What is Daratumumab Used For?

Daratumumab primarily treats multiple myeloma, a cancer that affects plasma cells in your bone marrow. Your doctor may prescribe it alone or combined with other cancer medications, depending on your specific situation.

The medication is approved for several scenarios. You might receive it if you're newly diagnosed with multiple myeloma, if your cancer has returned after previous treatments, or if other therapies haven't worked as hoped. Sometimes doctors use it for light chain amyloidosis, a related condition where abnormal proteins build up in your organs.

Your healthcare team will determine if daratumumab is right for you based on your cancer type, overall health, and treatment history. Each person's cancer journey is unique, so your treatment plan will be tailored specifically to your needs.

How Does Daratumumab Work?

Daratumumab works by targeting a protein called CD38 that sits on the surface of multiple myeloma cells. When the medication binds to this protein, it essentially puts a bullseye on the cancer cell for your immune system to recognize and destroy.

This is considered a strong and effective medication in the cancer treatment world. Unlike traditional chemotherapy that affects both healthy and cancerous cells, daratumumab is more selective in its approach. It primarily targets cells with high levels of CD38, which includes most myeloma cells.

The medication works through multiple mechanisms. It can directly kill cancer cells, recruit immune cells to attack the marked cancer cells, and block certain pathways that cancer cells use to survive and grow. This multi-pronged approach makes it particularly effective against stubborn cancer cells.

How Should I Take Daratumumab?

Daratumumab is always given as an intravenous infusion in a healthcare facility, never at home. Your healthcare team will insert a small tube into a vein in your arm or through a central line if you have one.

Before each infusion, you'll receive pre-medications to help prevent allergic reactions. These typically include antihistamines, corticosteroids, and fever reducers. Taking these medications about 30 minutes to an hour before your daratumumab infusion helps your body handle the treatment more comfortably.

The infusion itself takes several hours, especially during your first few treatments. Your first infusion might take 6-8 hours because your team will start the medication slowly and monitor you closely. Subsequent infusions usually take 3-4 hours as your body becomes accustomed to the treatment.

You don't need to eat anything special before treatment, but staying well-hydrated is important. Bring snacks, entertainment, and comfortable clothes since you'll be sitting for several hours. Many treatment centers have recliners and amenities to help you stay comfortable during the process.

How Long Should I Take Daratumumab For?

The length of daratumumab treatment varies significantly based on your specific situation and how well you respond to the medication. Some people receive it for several months, while others may need it for a year or longer.

Initially, you'll likely receive infusions weekly for the first two months, then every two weeks for the next four months. After that, many people transition to monthly infusions. This schedule allows your body to adjust while maintaining effective cancer-fighting levels of the medication.

Your doctor will monitor your progress through regular blood tests and imaging scans. If your cancer responds well and side effects remain manageable, you might continue treatment for an extended period. The goal is to keep your cancer controlled while maintaining your quality of life.

Never stop taking daratumumab without discussing it with your healthcare team first. Even if you feel better, the medication might still be working to keep cancer cells at bay. Your doctor will help you understand when it's appropriate to consider stopping or changing your treatment plan.

What Are the Side Effects of Daratumumab?

Like all cancer medications, daratumumab can cause side effects, though many people tolerate it well. The most common side effects are generally manageable with proper care and monitoring from your healthcare team.

Here are the side effects you're most likely to experience, and knowing about them can help you feel more prepared:

• Fatigue and tiredness, which often improves as your body adjusts to treatment
• Nausea and sometimes vomiting, usually mild and controllable with anti-nausea medications
• Back pain and muscle aches that may come and go
• Diarrhea or constipation, both manageable with dietary changes and medications
• Decreased appetite, which is common but typically temporary
• Cough or upper respiratory symptoms that usually resolve on their own
• Low blood cell counts, which your doctor will monitor closely through regular blood tests

These common side effects affect many people but are usually mild to moderate and improve over time. Your healthcare team has experience managing these symptoms and can provide strategies to help you feel better.

Some people experience infusion reactions, which can happen during or shortly after receiving the medication. These reactions might include fever, chills, difficulty breathing, or skin rash. The pre-medications you receive help prevent these reactions, and your healthcare team monitors you closely during each infusion.

Less common but more serious side effects can occur, though they affect fewer people. These include severe infections due to lowered immune function, significant drops in blood cell counts, or liver problems. Your doctor will watch for these through regular monitoring and can adjust your treatment if needed.

Very rare side effects might include severe allergic reactions, heart problems, or secondary cancers, but these occur in a small percentage of people. While concerning, the benefits of controlling your primary cancer typically outweigh these rare risks.

Who Should Not Take Daratumumab?

Daratumumab isn't suitable for everyone, and your doctor will carefully evaluate whether it's safe for you. People with severe active infections should typically wait until the infection clears before starting treatment.

If you have a history of severe allergic reactions to monoclonal antibodies or any components of daratumumab, your doctor will likely recommend alternative treatments. Those with certain heart conditions or severe liver problems may also need different treatment options.

Pregnancy and breastfeeding are important considerations. Daratumumab can harm an unborn baby, so women who could become pregnant need effective birth control during treatment and for several months afterward. If you're breastfeeding, you'll need to stop before starting daratumumab.

People with certain blood disorders or those who've had severe reactions to blood transfusions may need special precautions. Your doctor will review your complete medical history to determine if daratumumab is the right choice for your situation.

Daratumumab Brand Names

Daratumumab is available under the brand name Darzalex for intravenous infusion. You might also hear about Darzalex Faspro, which is a subcutaneous version that's injected under the skin rather than through an IV.

Both forms contain the same active ingredient and work similarly, but the delivery method differs. Your doctor will choose the most appropriate form based on your specific needs, treatment schedule, and personal preferences.

Daratumumab Alternatives

Several other medications can treat multiple myeloma if daratumumab isn't suitable for you. These alternatives work through different mechanisms but aim to achieve similar goals of controlling your cancer.

Other monoclonal antibodies like elotuzumab or isatuximab target different proteins on cancer cells. Traditional chemotherapy drugs, immunomodulatory drugs like lenalidomide, or proteasome inhibitors such as bortezomib might be options depending on your situation.

CAR-T cell therapy represents another innovative approach where your own immune cells are modified to fight cancer more effectively. Stem cell transplant might be considered for some people, especially younger patients with good overall health.

Your healthcare team will discuss all appropriate options with you, considering your cancer's characteristics, your overall health, previous treatments, and personal preferences. The best treatment is often a combination approach tailored specifically to your needs.

Is Daratumumab Better Than Bortezomib?

Comparing daratumumab to bortezomib isn't straightforward because they work differently and are often used together rather than as competing alternatives. Both are effective cancer medications, but they target different aspects of multiple myeloma.

Bortezomib is a proteasome inhibitor that disrupts how cancer cells process proteins, while daratumumab uses your immune system to attack cancer cells directly. Many treatment regimens combine both medications because they complement each other's effects.

In terms of side effects, they differ significantly. Bortezomib commonly causes peripheral neuropathy (nerve damage in hands and feet), while daratumumab more often causes fatigue and infusion reactions. Some people tolerate one better than the other.

Studies show that combining daratumumab with bortezomib-based regimens often produces better results than using bortezomib alone. Your doctor will consider your specific cancer characteristics, previous treatments, and overall health when deciding which approach is best for you.